SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nikes fiscal first-quarter results and weak full-year outlook are driving attention, with revenue declinesespecially in Chinaand expectations of a prolonged recovery weighing on shares. Traders are split between seeing the EPS beat, improved margins and dividend as reasons to accumulate, and viewing continued sales weakness and managements turnaround plan as signs of further downside.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins sharp selloff is being tied mainly to Wells Fargos assessment that the surge in e-commerce pixel installations may be low quality, renewing concerns about whether the expansion can drive meaningful ad revenue; traders also cite competition from Unity and ongoing litigation. The community is split between seeing a falling knife amid possible growth and valuation risks and calling the decline an overreaction, with some buying the dip based on AppLovins cash generation and core ad-tech business.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Evernorths approved business combination with Armada and planned Nasdaq listing as an XRP treasury company are driving attention, with the deal expected to bring roughly 473 million XRP into the treasury. Traders are split between bullish bets on XRP exposure and a potentially tight float, including interest in warrants, and warnings that the sharp rally may be speculative and vulnerable to profit-taking.

Corteva, Inc. is a global pure-play agriculture company that combines innovative technologies, high-touch customer engagement and operational execution to profitably deliver solutions for the world's most pressing agriculture challenges. It generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. The company leverages recognized agricultural brands and a robust technology pipeline to maximize productivity for farmers while working with stakeholders throughout the food system to fulfill its promise of enriching the lives of those who produce and those who consume, ensuring progress for generations to come. Corteva was founded in 1802 and is headquartered in Indianapolis, IN.

Corteva Inc

Cortevas completed spin-off of its seed and genetics business into Vylor has dominated discussion: CTVA now represents the standalone crop-protection business, so much of the sharp share-price reset reflects the separation rather than a comparable loss in combined shareholder value. Traders are split between viewing the selloff as an overshoot and a buying opportunity, and worrying that the remaining business may face further pressure as the market reprices it.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

onsemis revised Synaptics acquisition, shifting from stock to cash after a competing proposal, is the dominant catalyst; traders view the lower-cost structure as more attractive for ON shareholders and welcomed the news, alongside bullish technical chatter.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Traders are focused on ALAB missing out on S&P 500 inclusion after speculation around a possible addition, with some attributing the post-announcement weakness to the snub. The community is split between buying the pullback on the AI-connectivity growth story and concerns about valuation and further volatility.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

Renewed optimism around XRP ETF demand and potential approvals, alongside regulatory-clarity speculation and institutional interest, is drawing attention to the fund. Traders are debating whether momentum can continue, while some posts also show confusion between the ETF ticker and XRP itself.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Globals 20-year LNG supply agreement with ConocoPhillips is driving attention, with traders viewing the contract as validation of demand for its expanding export capacity. Reactions are divided: some see it as positive long-term revenue visibility, while others question the delayed start and whether committing volumes sacrifices higher-margin spot sales; concerns about insider selling and choppy trading also persist.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Citis Buy initiation has renewed attention on Nuvations oncology assets, especially IBTROZIs ROS1 lung-cancer franchise and safusidenibs glioma potential. Many traders are bullish on the pipeline and speculate about institutional buying or a future acquisition, while others point to weak share performance, short interest, and competitive risks.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektars 52-week rezpeg update in alopecia and atopic dermatitis is driving attention as shares fell sharply despite signs that some benefits persisted with less-frequent or discontinued dosing. Traders are split between viewing the durability findings as encouraging and seeing the modest responses from small patient groups as disappointing; some also call the selloff overdone.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CORT With 9.4M shares shorted, which is about 9% outstanding or 11% float, we will only trade sideways for a while until the next catalysts such as Relacorilant/CS approval in US, Lifyorli approval in EU, and/or Q3 ER - all in 2027. These catalysts should advance SP to north of $150.

More exciting are the clinical advancement of Dazucorilant/ALS and Miricorilant/MASH to P3 trials. Hopefully, at least one of the two will be in H1/27, or both. The initiation of these two P3 trials will further advance SP to above $200.

Then in 2028, we should see all four franchises firing - CS, PROC, ALS, and MASH, which are all $B- dollar blockbuster drugs. If not acquired and no split by then, we should see SP reaches north of $300. GL &amp; cheers!

$CORT Correction: It should be &quot;all in 2026&quot; in the first paragraph.

StockTwits For Android 

Wyane

Corcept Therapeutics Inc

Barrick Mining Corp

 With 9.4M shares shorted, which is about 9% outstanding or 11% float, we will only trade sideways for a while until the next catalysts such as Relacorilant/CS approval in US, Lifyorli approval in EU, and/or Q3 ER - all in 2027. These catalysts should advance SP to north of $150.

More exciting are the clinical advancement of Dazucorilant/ALS and Miricorilant/MASH to P3 trials. Hopefully, at least one of the two will be in H1/27, or both. The initiation of these two P3 trials will further advance SP to above $200.

Then in 2028, we should see all four franchises firing - CS, PROC, ALS, and MASH, which are all 

- dollar blockbuster drugs. If not acquired and no split by then, we should see SP reaches north of $300. GL & cheers!